Navigation Links
Reportlinker Adds Successful Strategies for Drug Repositioning
Date:4/20/2011

NEW YORK, April 20, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Successful Strategies for Drug Repositioning

http://www.reportlinker.com/p0483598/Successful-Strategies-for-Drug-Repositioning.html

Introduction

This report Highlights how drug repositioning can provide a low-risk approach to drug development. The success of the approach is illustrated by a number of case histories, mostly arising from serendipitous observations. The report illustrates systematic approaches to identify suitable opportunities that should lead to better success including those being pursued by specialist companies.

Features and benefits

* Analyze and understand the strategies employed in the most successful examples of drug repositioning.

* Discover the key technologies required to establish potential repositioning opportunities.

* Identify the specialist service providers with expertise in the key technologies required to systematically identify repositioning candidates.

* Discover how through repositioning a company can protect its intellectual property.

* Analyze the potential impact that drug repositioning can have on both large pharma companies and small specialist companies.

Highlights

The pharma industry's revenue growth is low and it is failing to introduce sufficient new drugs to offset the impact of patent expirations despite record R&D costs. Repurposing of drugs offers a lower risk, lower cost, approach to new product development. Repurposing of development failures can recover what would otherwise be lost R&D expenditure.

The potential commercial benefits from successful repositioning of a drug are likely to be greater than those offered by simple reformulation, and offers opportunities for extended periods of market exclusivity via the granting of additional patents.

Major companies are well positioned to benefit from the successful repurposing of drugs, especially when they utilize both internal resources and external resources. The effective application of repurposing technologies should enable major companies to significantly enhance their development pipelines.

Your key questions answered

* What are the current advantages of repositioning over other lower risk approaches to drug development?

* What are the key technologies being used to identify new targets for molecules in companies' databases?

* How does drug repositioning improve the intellectual property position of companies that employ this strategy?

* What skills and platforms do specialist companies engaged in drug repositioning possess?

* How have molecules such as sildenafil and thalidomide been repositioned successfully?

TABLE OF CONTENTS

Executive Summary

Chapter 1 Introduction

Chapter 2 Lower Risk Strategies

Chapter 3 What is Repositioning?

Chapter 4 Strategic Approaches to Repositioning

Chapter 5 Successful case studies

Chapter 6 Current Efforts

Chapter 7 Specialist Companies

Chapter 8 Outlook

About the author

Disclaimer

Introduction

Summary

Introduction

The decline in approvals of novel chemical entities

The costs, and risks, of drug development

Lower Risk Strategies

Summary

Introduction

Enantiomeric switches

Active metabolites

Reformulation

Repositioning

What is Repositioning?

Summary

Overview

Commercial implications

Intellectual property issues

Design or serendipity?

Strategic Approaches to Repositioning

Summary

Introduction

Chemical space

New indications

Phenotypic approaches

Informatics-based approaches

Reformulation

Exploiting intellectual property

Increased licensing opportunities

Successful case studies

Summary

Introduction

Bupropion

Minoxidil

Thalidomide

Bosentan

sildenafil (Viagra and Revatio)

Current Efforts

Summary

Introduction

Major opportunities

Rare diseases

Drugs in advanced development

Inhaled formulations

Biological products

Modified formulations

Repurposing by combination

Other approaches

Specialist Companies

Summary

Introduction

Almac Group

Ampio Pharmaceuticals

Anaxomics Biotech

APT Pharmaceuticals

Aureus Sciences

Biovista

Celentyx

Cypress Bioscience

Essentialis

Horizon Discovery

Jenken Biosciences

Melior Discovery

NeuroHealing Pharmaceuticals

Numedicus

OphSmart

Optimata

Ore Pharmaceutical Holdings

Radical Therapeutix

SOM Biotech

Somaxon Pharmaceuticals

Sosei Group

SWITCH Biotech

Tangent Reprofiling

Zalicus

Outlook

Summary

Introduction

Impact on major companies

Impact for specialist companies

Overall perspective

Appendix

Glossary/Abbreviations

Bibliography/References

To order this report:

: Successful Strategies for Drug Repositioning

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Middle Eastern Medical Device Market: Facts and Figures2011
2. Reportlinker Adds Levosimendan - Comprehensive patent search
3. Reportlinker Adds Zolpidem - Key patent, SPC, and data exclusivity expiry (44 country coverage)
4. Reportlinker Adds North America Dental Devices Market Outlook to 2017
5. Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices
6. Reportlinker Adds ENT Devices Market Outlook in United States to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices
7. Reportlinker Adds Companion Diagnostics Partnering Terms and Agreements
8. Reportlinker Adds ENT Devices Market Outlook in China to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices
9. Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
10. Reportlinker Adds Neurology Devices Market Outlook in United States to 2017 - Neurostimulation Devices, Interventional Neurology and Others
11. Reportlinker Adds Arthritis Therapy Area Pipeline Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at http://www.rebound-solution.com/ ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: ... data solutions, today announced that its MyDario product is expected to appear ... listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The ... ...
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's (ABFM) ... and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton ... until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role of ...
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
Breaking Medicine News(10 mins):